BEIJING--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has announced a long-term strategic partnership with Beijing Biostar Pharmaceuticals Co., Ltd.

北京--（商业新闻短讯）--全球全方位服务临床合同研究组织（CRO）Novotech宣布与北京生物星制药有限公司建立长期战略合作伙伴关系，该组织与生物技术公司合作，在每个阶段加快先进和新型治疗剂的开发。

(2563.HK) (“Biostar”). This collaboration strengthens the commitment of both companies to advance clinical research, leveraging Novotech’s expertise and technical platforms to support Biostar’s clinical development plans..

（2563.HK）（“Biostar”）。这种合作加强了两家公司推进临床研究的承诺，利用Novotech的专业知识和技术平台来支持Biostar的临床开发计划。。

Biostar, a leader in synthetic biology and oncology development in China, recently marked a significant milestone with its successful listing on the Hong Kong Stock Exchange, symbolizing a new phase of growth. Novotech was honored to attend Biostar’s listing ceremony and appreciation banquet to celebrate this achievement..

Biostar是中国合成生物学和肿瘤学发展的领导者，最近在香港证券交易所成功上市，标志着一个重要的里程碑，标志着一个新的增长阶段。Novotech很荣幸参加Biostar的上市仪式和感谢宴会，以庆祝这一成就。。

Dr. Li Tang, Chairman, Executive Director, Chief Scientific Officer, and Chief Marketing Officer of Biostar, stated: “As a biopharmaceutical company driven by synthetic biology technology, Biostar is committed to developing innovative oncology drugs. Our successful listing is a major milestone in our development and a new beginning.

Biostar董事长、执行董事、首席科学官和首席营销官李唐博士表示：“作为一家由合成生物学技术驱动的生物制药公司，Biostar致力于开发创新的肿瘤药物。我们的成功上市是我们发展的一个重要里程碑，也是一个新的开始。

Going forward, we will continue to focus on research and innovation, bring more innovative drug products to market, and extend our current products to more patients, contributing significantly to the health and wellness sector.”.

展望未来，我们将继续专注于研究和创新，将更多创新的药品推向市场，并将我们目前的产品扩展到更多的患者，为健康和健康部门做出重大贡献。”。

Mr. Andy Liu, General Manager of Novotech China, added: “Congratulations to Biostar on their successful listing. The successful listing of Biostar is an exhilarating milestone that showcases the relentless efforts and remarkable achievements of Biostar in the biotech field. As a strategic partner in Biostar’s research phase, we are confident in our future collaboration and look forward to supporting Biostar as it expands into international markets, bringing more innovative and advanced health solutions to a global audience.”.

Novotech China总经理刘德华先生补充道：“祝贺Biostar成功上市。Biostar的成功上市是一个令人振奋的里程碑，展示了Biostar在生物技术领域的不懈努力和卓越成就。作为Biostar研究阶段的战略合作伙伴，我们对未来的合作充满信心，并期待着在Biostar进军国际市场时为其提供支持，为全球观众带来更多创新和先进的健康解决方案。”。

This strategic partnership highlights Novotech’s commitment to partnering with biotech innovators in their journey from development to market, reinforcing the company’s role as a trusted CRO in the global clinical research landscape.

这一战略伙伴关系突显了Novotech在从开发到市场的过程中与生物技术创新者合作的承诺，加强了该公司在全球临床研究领域中作为值得信赖的CRO的作用。

About Novotech Novotech-CRO.com

关于Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Novotech成立于1997年，是一家全球全方位服务的临床合同研究组织（CRO），专注于与生物技术公司合作，以加速各个阶段先进和新颖疗法的开发。

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006..

Novotech因其行业领先的贡献而备受赞誉，它获得了众多久负盛名的奖项，包括Frost&Sullivan 2024年全球生物技术首席执行官年度奖、临床试验领域卓越奖2024年、2024年雇主选择奖、2024年美国工作大典、2024年布兰登·霍尔金奖、2023年首席执行官领导力奖、2023年亚太细胞与基因治疗临床试验卓越奖、2006年以来的亚太合同研究组织年度公司奖。。

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice..

该公司提供一整套服务，包括实验室、一期设施、药物开发咨询、监管专业知识，并拥有5000多个临床项目的经验，包括一期至四期临床试验和生物等效性研究。Novotech在全球34个办公地点设有办事处，拥有3000多名专业人员组成的专门团队，是值得信赖的端到端战略合作伙伴。。

For more information or to speak to an expert team member visit www.Novotech-CRO.com

欲了解更多信息或与专家团队成员交谈，请访问www.Novotech-CRO.com